<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFEPIME HYDROCHLORIDE</span><br/>(cef'e-peem)<br/><span class="topboxtradename">Maxipime<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">fourth-generation cephalosporin</span><br/><b>Prototype: </b>Cefotaxime sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg, 1 g, 2 g vials</p>
<h1><a name="action">Actions</a></h1>
<p>Cefepime, considered to be a fourth-generation cephalosporin antibiotic, is similar to third-generation cephalosporins with
         respect to broad gram-negative coverage; however, cefepime has broader gram-positive coverage than third-generation cephalosporins.
         It is highly resistant to hydrolysis by most beta-lactamase bacteria. Cefepime preferentially binds to one or more of the
         penicillin-binding proteins (PBPs) located on cell walls of susceptible organisms. This inhibits the third and final stage
         of bacterial cell wall synthesis, thus killing the bacteria (bactericidal).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effectively treats pneumonia, skin and soft tissue infections, febrile neutropenia, respiratory tract, intra-abdominal infections,
         and urinary tract infections by reducing or eliminating signs and symptoms of infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Uncomplicated and complicated UTI, skin and skin structure infections, pneumonia caused by susceptible organisms (<i>Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus aureus</i> [methicillin-sensitive], <i>Streptococcus pyogenes, Streptococcus pneumoniae, Pseudomonas aeruginosa, Enterobacter</i> sp). Empiric monotherapy for febrile neutropenic patients.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cefepime, other cephalosporins, penicillins, or other beta-lactam antibiotics.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with history of GI disease, particularly colitis, renal insufficiency; pregnancy (category B), lactation. Safety
         and efficacy of cefepime in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Mild to Moderate Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 0.51g q12h times 710 d<br/><br/><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 12g q12h times 10 d<br/><br/><span class="indicationtitle">Febrile Neutropenia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 2 g q8h for 7 d or until resolution of neutropenia<br/><br/><span class="impairmenttitle">Adjustment for Renal Impairment</span><br/>Cl<sub>cr</sub> 3060 mL/min: dose q24h; 1129 mL/min: give 50% of normal dose q24h; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reconstitute 500-mg vial and 1-g vial, respectively, with 1.3 or 2.4 mL of one of the following: Sterile Water for Injection,
            0.9% NaCl Injection, Bacteriostatic Water for Injection with Parabens or benzyl alcohol, or other compatible solution.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Dilute with 50100 mL of one of the following: NS, D5W, D5/NS or other compatible solution.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span>  Infuse over 30 min; with Y-type administration set, discontinue other compatible solutions while infusing cefepime.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<span class="classification">aminoglycosides</span>, <b>ampicillin,</b>
<b>aminophylline,</b>
<b>metronidazole.</b>
<span class="incompattype">Y-site:</span>
<b>Acyclovir,</b>
<b>amphotericin B,</b>
<b>amphotericin B cholesteryl complex,</b>
<b>chlordiazepoxide,</b>
<b>chlorpromazine,</b>
<b>cimetidine,</b>
<b>ciproxfloxacin,</b>
<b>cisplatin,</b>
<b>dacarbazine,</b>
<b>daunorubicin,</b>
<b>diazepam,</b>
<b>diphenhydramine,</b>
<b>dobutamine,</b>
<b>dopamine,</b>
<b>doxorubicin,</b>
<b>droperidol,</b>
<b>enalaprilat,</b>
<b>etoposide,</b>
<b>famotidine,</b>
<b>filgrastim,</b>
<b>floxuridine,</b>
<b>ganciclovir,</b>
<b>haloperidol,</b>
<b>hydroxyzine,</b>
<b>idarubicin,</b>
<b>ifosfamide,</b>
<b>magnesium sulfate,</b>
<b>mannitol,</b>
<b>mechlorethamine,</b>
<b>meperidine,</b>
<b>metoclopramide,</b>
<b>mitomycin,</b>
<b>mitoxantrone,</b>
<b>morphine,</b>
<b>nalbuphine,</b>
<b>ofloxacin,</b>
<b>ondansetron,</b>
<b>plicamycin,</b>
<b>prochlorperazine,</b>
<b>promethazine,</b>
<b>streptozocin,</b>
<b>vancomycin,</b>
<b>vinblastine,</b>
<b>vincristine.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store reconstituted solution at 20°25° C (68°77° F) for 24 h or in refrigerator at 2°8°
            C (36°46° F) for 7 days. Protect from light.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Eosinophilia. <span class="typehead">GI:</span> Antibiotic-associated colitis, diarrhea, nausea, oral moniliasis, vomiting, elevated liver function tests (ALT, AST). <span class="typehead">CNS:</span> Headache, fever. <span class="typehead">Skin:</span> Phlebitis, pain, inflammation, rash, pruritus, urticaria. <span class="typehead">Urogenital:</span> Vaginitis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Positive <span class="alt">Coombs' test</span> without hemolysis. May cause false-positive <span class="alt">urine glucose test</span> with <span class="alt">Clinitest.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> A<span class="classification">minoglycosides</span> may increase risk of nephrotoxicity and have additive/synergistic effects. May decrease efficacy of <span class="classification">oral contraceptives</span>. <b>Probenecid</b> may increase levels. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed after IM administration; serum levels significantly lower than after equivalent IV dose. <span class="typehead">Distribution:</span> 20% protein bound, widely distributed, may cross inflamed meninges; crosses placenta, secreted into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine history of hypersensitivity reactions to cephalosporins, penicillins, or other drugs before therapy is initiated.</li>
<li>Lab tests: Perform culture and sensitivity tests before initiation of therapy. Dosage may be started pending test results.</li>
<li>Monitor for S&amp;S of hypersensitivity (see Appendix F). Report their appearance promptly and discontinue drug.</li>
<li>Monitor for S&amp;S of superinfection or pseudomembranous colitis (see Appendix F); immediately report either to physician.</li>
<li>With concurrent high-dose aminoglycoside therapy, closely monitor for nephrotoxicity and ototoxicity.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Promptly report any S&amp;S of hypersensitivity, superinfection, and pseudomembranous colitis.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>